Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 18 2021 - 8:30AM
Cara Therapeutics, Inc. (Nasdaq: CARA), an early
commercial-stage biopharmaceutical company focused on developing
and commercializing new chemical entities designed to alleviate
pruritus by selectively targeting peripheral kappa opioid
receptors, today announced that Christopher Posner, President and
Chief Executive Officer, Thomas Reilly, Chief Financial Officer,
and Joana Goncalves, M.D., Chief Medical Officer, will participate
in a fireside chat at the Piper Sandler 33rd Annual Virtual
Healthcare Conference. The fireside chat will be available
beginning Monday, November 22, 2021 at 10:00 a.m. ET.
A webcast of the fireside chat can be accessed
under "Events & Presentations" in the News & Investors
section of the Company's website at www.CaraTherapeutics.com. An
archived webcast recording will be available on the Cara website
for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is an early commercial-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body’s peripheral nervous system, as well as
certain immune cells. KORSUVA Injection was approved by the U.S.
Food and Drug Administration (FDA) for the treatment of
moderate-to-severe pruritus associated with chronic kidney disease
(CKD-aP) in adults undergoing hemodialysis on August 23, 2021. Oral
KORSUVA has completed Phase 2 trials for the treatment of pruritus
in patients with CKD and atopic dermatitis and is currently in
Phase 2 trials in primary biliary cholangitis and notalgia
paresthetica patients with moderate-to-severe pruritus.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.212-362-1200janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024